Mr. Paul Glavine reports

LGC CAPITAL ANNOUNCES FIRST COMMERCIAL SALES OF MEDICAL CANNABIS IN JAMAICA FROM GLOBAL CANNA LABS

LGC Capital Ltd. investment Global Canna Labs received its formal approvals late in March from the Jamaican Cannabis Licensing Agency (CLA) to commence commercial medical cannabis sales domestically to licensed dispensaries.

As of today, Global Canna Labs has now sold a total of 46.5 kilograms of dried medical cannabis products to the local dispensaries. It is now receiving regular domestic sales inquiries and demand for Global Canna Labs' products is expected to accelerate from here.

LGC also advises that Global Canna Labs has now planted out the majority of its 6.2-acre site in Montego Bay and expects to commence harvesting, under CLA supervision, two sectional harvests per months from various phases of crop growth and various cannabis strains, with the first of these bimonthly harvests scheduled for April 10.

Global Canna Labs is one of the very few Tier 3 licences in Jamaica for the cultivation and production of medical cannabis (licensed to cultivate and produce over five acres), after formally receiving its full approval for a Tier 3 cultivation licence from the Jamaican Cannabis Licensing Agency (CLA) in July, 2018. This licence allows GCL to cultivate medical cannabis at its 6.23-acre site in Montego Bay in Jamaica. GCL is planning on opening two dispensaries and an extraction facility in the very near future.

Mazen Haddad, co-chairman and chief executive officer of LGC Capital, stated: "This is a tremendous achievement for the team in Jamaica. We have seen many achievements within Global Canna Labs since LGC became a cornerstone funder of this exciting company. We see them continuing to expand and grow at their facility in Montego Bay, as the market demand grows. Senior LGC management recently toured the Montego Bay facility to witness operations almost at full planting capacity and witnessed the results of the first harvests. There is still scope to infill sections of the 6.2-acre site before looking to expand beyond the existing secured growing areas. We see Jamaica as a very key growth market in the area and can see considerable expansion opportunities for Global Canna Labs as a Jamaican leader in their field, as the domestic and internal markets for Jamaica's special brand of organic sativa strains and find their place in the market."

LGC has a secured debenture, convertible into a 30-per-cent strategic interest in Global Canna Labs and a 5-per-cent royalty on Global Canna Labs' net sales.

About LGC Capital Ltd.

Through its partners and assuming pending transactions under review by the TSX Venture Exchange are approved, LGC presently will have interests in over 450,000 square feet of planted cannabis in Jamaica, Switzerland, Italy, and Australia. That is expected to increase to over 2.1 million square feet by 2021, as its portfolio companies execute their expansion plans, in addition to the anticipated licensing of Tricho-Med's operations in Quebec, Canada.

We seek Safe Harbor.